10 June 2021
- British Summer Time (BST), 9:00 am
- Central European Summer Time (CEST), 10:00 am
- Central Africa Time (CAT), 10:00 am
- Moscow Standard Time (MSK), 11:00 am
- Indian Standard Time (IST), 13:30 pm
- China Standard Time (CST), 14:00 pm
- Australia Eastern Standard Time (AEST), 18 pm
ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC was running a series of ‘Evidence Fora’ on COVID-19 treatment.
Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus. Infusion of convalescent plasma containing high concentrations of neutralising antibody may theoretically accelerate clearance of the virus and clinical improvement. Although convalescent plasma has been widely used in patients admitted to hospital with COVID-19, data from randomised controlled trials in this patient group have, until recently, been limited.
This webinar provides evidence from randomised controlled trials of the safety and efficacy of convalescent plasma in patients hospitalised for COVID-19.
International Public Health Specialist, George Institute for Global Health
Lead of COVID-19 clinical care, WHO
Executive Director, ISARIC
Senior Scientist, Indian Council of Medical Research
Consultant in Critical Care, Department of Critical Care, Apollo Hospitals
Objectives of this forum:
- To provide up-to-date information from randomised controlled trials on evidence of the effectiveness and safety of convalescent plasma in patients admitted to hospital with COVID-19.
- To identify key questions for translating the clinical trial evidence on the use of convalescent plasma in patients admitted to hospital with COVID-19 into clinical practice.